(Val 8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

European Journal of Pharmacology

Volumn 674, Issue 2-3, 2012, Pages 280-286

  Li, Lin ^a   Zhang, Zhi Feng ^b   Holscher, Christian ^c   Gao, Chong ^a   Jiang, Yuan Hong ^a   Liu, Yue Ze ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Glucagon like peptide 1; Phosphoralyted tau

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [8 VALINE]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; STREPTOZOCIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CELL DAMAGE; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; LEARNING; LEARNING DISORDER; MALE; MAZE TEST; MEMORY; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SPATIAL MEMORY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; LEARNING; MALE; MAZE LEARNING; MEMORY; PHOSPHOPROTEINS; PHOSPHORYLATION; RATS; RATS, WISTAR; SPATIAL BEHAVIOR; STREPTOZOCIN; TAU PROTEINS;

EID: 84855548096     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.11.005     Document Type: Article

References (27)

1. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., Iqbal, K., 2001. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U. S. A. 98, 6923-6928. (Pubitemid 32538318)
2. Barreda, E.G., Avila, J., 2011. Is tau a suitable therapeutical target in tauopathies? World J. Biol. Chem. 1, 81-84.
3. Biswas, S.C., Buteau, J., Greene, L.A., 2008. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res. 33, 1845-1851.
4. Chen, S., Liu, A.R., An, F.M., Yao, W.B., Gao, X.D., 2011. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr). doi:10.1007/s11357-011-9303-8.
5. Gault, V.A., Flatt, P.R., Harriott, P., Mooney, M.H., Bailey, C.J., O'Harte, F.P., 2003. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J. Endocrinol. 176, 133-141. (Pubitemid 36163574)
6. Gengler, S., Gault, V., Harriott, P., Hölscher, C., 2007. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp. Brain Res. 179, 621-630. (Pubitemid 46800598)
7. Gengler, S., McClean, P., McCurtin, R., Gault, V., Holscher, C., 2010. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging. doi:10.1016/j.neurobiolaging.2010.1002.1014.
8. Hölscher, C., Li, L., 2010. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging 31, 1495-1502.
9. Ishrat, T., Parveen, K., Khan, M.M., Khuwaja, G., Khan, M.B., Yousuf, S., Ahmad, A., Shrivastav, P., Islam, F., 2009. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res. 1281, 117-127.
10. Kosik, K.S., Orecchio, L.D., Bakalis, S., Neve, R.L., 1989. Developmentally regulated expression of specific tau sequences. Neuron 4, 1389-1397.
11. Kroner, Z., 2009. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern. Med. Rev. 14, 373-379.
12. Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasiñski, A., Grieb, P., 2010. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir. Suppl. 106, 177-181.
13. Li, L., Hölscher, C., 2007. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402. (Pubitemid 350166529)
14. Li, Y., Duffy, K., Ottinger, M., Ray, B., Bailey, J., Holloway, H., Tweedie, D., Perry, T., Mattson, M., Kapogiannis, D., Sambamurti, K., Lahiri, D., Greig, N., 2010. GLP-1 Receptor Stimulation Reduces Amyloid-beta Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. J. Alzheimers Dis. 19, 1205-1219.
15. Lu, W., Tang, H., Fan, M., Wang, L., Jia, J., 1998. Research on nucleolar organizer regions of hippocampal neuron in Alzheimer's disease. Chin. Med. J. 111, 282-284. (Pubitemid 128515297)
16. Mandelkow, E., Song, Y.-H., Schweers, O., Marx, A., Mandelkow, E.-M., 1995. On the structure of microtubules, tau, and paired helical filaments. Neurobiol Aging 16, 347-354.
17. McClean, P.L., Gault, V.A., Harriott, P., Hölscher, C., 2010. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158-162.
18. McClean, P., Parthsarathy, V., Faivre, E., Hölscher, C., 2011. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
19. Morris, R.G., 1984. Developments of a water maze producer for studying spatial learning in the rats. J. Neurosci. Meth. 11, 47-60.
20. National Institutes of Health Publications, No. 80-23, revised 1978.
21. Nunomura, A., Perry, G., Pappolla, M.A., Wade, R., Hirai, K., Chiba, S., Smith, M.A., 1999. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964. (Pubitemid 29133374)
22. Perry, T., Greig, N.H., 2005. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377-385. (Pubitemid 40980196)
23. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., Greig, N.H., 2003. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72, 603-612. (Pubitemid 36578646)
24. Scarpini, E., Scheltens, P., Feldman, H., 2003. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2, 539-547. (Pubitemid 36994993)
25. Sharma, M., Gupta, Y.K., 2001. Effect of chronic treatment of melatonin on learning, memory and oxidative deficiencies induced by intracerebroventricular streptozotocin in rats. Pharmacol. Biochem. Behav. 70, 325-331. (Pubitemid 33051001)
26. Wang, J.Z., Grundke-Iqbal, I., Iqbal, K., 2007. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68. (Pubitemid 46098893)
27. Wang, X.H., Li, L., Hölscher, C., Pan, Y.F., Chen, X.R., Qi, J.S., 2010. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal latephase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239-1248.